RXRX

Recursion Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 3/10
  • Value↓ 0/10
Recursion Pharmaceuticals sales and earnings growth
RXRX Growth
Neutral
  • Revenue Y/Y↑ 11.07%
  • EPS Y/Y↑ 35.91%
  • FCF Y/Y↑ 18.07%
Recursion Pharmaceuticals gross and profit margin trends
RXRX Profitability
Fair
  • Gross margin ↓ 7.20%
  • EPS margin↓ -842.90%
  • ROIC 5Y↓ -274.31%
Recursion Pharmaceuticals net debt vs free cash flow
RXRX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Recursion Pharmaceuticals stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks